Skip to content
lifestyle.hubspotes.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tenaya Therapeutics, Inc.
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
September 14, 2026
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
September 3, 2026
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 4, 2026
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 14, 2026
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
June 29, 2026
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
April 27, 2026
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
March 9, 2026
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026
March 2, 2026